Puma Biotechnology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M |
| Cost of Revenue | $58.2M | $64.4M | $62.7M | $55.1M | $63.7M | $39.4M | $36.8M | $34.6M |
| Gross Profit | $170.2M | $166.1M | $173.0M | $172.9M | $189.5M | $185.7M | $235.4M | $216.4M |
| Gross Margin | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $71.9M | $97.7M | $132.9M | $164.9M |
| SG&A Expense | $70.8M | $80.2M | $89.9M | $90.0M | $116.3M | $118.5M | $141.6M | $146.2M |
| Operating Income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M | $-30.4M | $-39.0M | $-94.7M |
| Operating Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | -13.5% | -14.3% | -37.7% |
| Interest Expense | — | — | $13.3M | $11.6M | $12.8M | $14.0M | $15.0M | $11.0M |
| Pretax Income | $35.8M | $24.1M | $22.7M | $457.0K | $-28.8M | $-59.8M | $-75.5M | $-113.6M |
| Income Tax Expense | $4.7M | $-6.2M | $1.1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K |
| Net Income | $31.1M | $30.3M | $21.6M | $2.0K | $-29.1M | $-60.0M | $-75.6M | $-113.6M |
| Net Margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% |
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75,595.00 | $-2.99 |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | $-1.95 | $-2.99 |
| Shares Outstanding (Basic) | 50.0M | 48.6M | 47.1M | 44.7M | 40.6M | 39.6M | 39.2M | 38.3M |
| Shares Outstanding (Diluted) | 50.7M | 49.1M | 47.6M | 44.9M | 40.6M | 39.6M | 39.2M | 38.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |